Publications by authors named "Yuri Sato-Nagaoka"
Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.
View Article and Find Full Text PDFArticle Synopsis
- Differentiation therapy with all-trans retinoic acid (ATRA) is effective for acute promyelocytic leukemia (APL), but there are limitations in its tolerance and application that prompted researchers to seek new inducers of myeloid differentiation.
- The study identified the kinase inhibitors PD169316, SB203580, SB202190, and triciribine (TCN) as potent enhancers of CD11b expression in APL cells, with a focus on TCN due to its good tolerance in patients.
- TCN promotes the differentiation of APL and acute myeloid leukemia (AML) cells by activating the ERK pathway and enhancing pathways associated with hematopoietic lineage and cytokine interactions, revealing